ArticleJournal of Ayurveda and integrative medicine
A randomized controlled study protocol to determine the safety and efficacy of Sivanarvembu Kuzhithailam in the management of Psoriasis (Kalanjagapadai).
Article in Journal of Ayurveda and integrative medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsoriasis is a chronic skin disorder with a substantial global burden, affecting over 100 million people worldwide. Conventional treatments, including topical and systemic therapies, have their own limitations and side effects. Siddha medicine, deeply rooted with comprehensive principles, offers an alternative approach in Psoriasis management. This randomized controlled trial aims to explore the safety and efficacy of Sivanarvembu Kuzhithailam, a classical Siddha medicine in the management of Psoriasis.
objectivesThe primary objective of this RCT is to determine the safety and efficacy of Sivanarvembu Kuzhithailam (SVK) and Vetpalai thailam and to reduce the PASI score in Psoriasis patients significantly. The secondary objective involves validating the biochemical changes in the study participants and determining enhancements in their quality of life before and after treatment. As a result, specific inflammatory markers, proteins, antioxidants, and assessments of oxidative stress have been undertaken in this clinical trial to provide deeper insights into the extent of inflammation, disease severity, and the mechanisms of action of the trial drug.
methodsThis is a single center, open-label, parallel group, exploratory randomized controlled trial with a sample size of 90 and with the objective of determining the safety and efficacy of Sivanarvembu Kuzhithailam in the management of psoriasis. This study protocol followed the SPIRIT 2013 guidelines.
resultThe primary outcome is to measure the reduction in the Psoriasis Area and Severity Index (PASI) score from baseline to 91 days and safety parameters. Secondary outcomes include the evaluation of enhancements in participants' quality of life through the assessment of the Dermatology Life Quality Index, as well as the examination of antioxidant levels, inflammatory markers, biochemical markers, in blood samples of trial participants.
conclusionThe outcome of the study can be extrapolated to the next level of clinical trials with larger populations to provide robust scientific evidence for this traditional Siddha formulation for global acceptance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.